1. |
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461. DOI: 10.1016/j.ccell.2015.03.001.
|
2. |
白日兰, 崔久嵬. 免疫检查点抑制剂治疗相关不良反应——新探索、新挑战[J]. 中国肿瘤生物治疗杂志, 2021, 28(5): 419-430. DOI: 10.3872/j.issn.1007-385x.2021.05.001.Bai RL, Cui JW. Immune checkpoint inhibitor-related adverse events: New exploration and new challenges[J]. Chinese Journal of Cancer Biotherapy, 2021, 28(5): 419-430. DOI: 10.3872/j.issn.1007-385x.2021.05.001.
|
3. |
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461. DOI: 10.1016/j.ccell.2015.03.001.
|
4. |
孙武, 茹姝婷, 史航, 等. 生物制剂诱发葡萄膜炎的研究进展[J]. 中国中医眼科杂志, 2024, 34(5): 489-493. DOI: 10.13444/j.cnki.zgzyykzz.2024.05.021.Sun W, Ru ST, Shi H, et al. Research progress on biologic agents inducing uveitis[J]. Chinese Journal of Chinese Ophthalmology, 2024, 34(5): 489-493. DOI: 10.13444/j.cnki.zgzyykzz.2024.05.021.
|
5. |
Xiao J, Wang S, Chen L, et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages[J]. Immunity, 2024, 57(5): 1087-1104. DOI: 10.1016/j.immuni.2024.03.021.
|
6. |
Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes[J]. Ocul Immunol Inflamm, 2021, 29(1): 203-211. DOI: 10.1080/09273948.2020.1781902.
|
7. |
Baughman DM, Lee CS, Snydsman BE, et al. Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma[J/OL]. Med Case Rep (Wilmington), 2017, 3(2): 8[2017-04-14]. https://pubmed.ncbi.nlm.nih.gov/28856338/. DOI: 10.21767/2471-8041.100044.
|
8. |
Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma[J/OL]. Pharmacotherapy, 2016, 36(11): e183-e188[2016-10-26]. https://pubmed.ncbi.nlm.nih.gov/27716999/. DOI: 10.1002/phar.1839.
|
9. |
Richardson DR, Ellis B, Mehmi I, et al. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report[J]. Int J Ophthalmol, 2017, 10(7): 1183-1186. DOI: 10.18240/ijo.2017.07.28.
|
10. |
张书培, 杨磊, 顾康生. PD-1/PD-L1抑制剂治疗晚期肿瘤患者免疫相关不良事件的预后价值[J]. 临床肿瘤学杂志, 2022, 27(2): 109-116. DOI: 10.3969/j.issn.1009-0460.2022.02.003.Zhang SP, Yang L, Gu KS. Prognostic value of immune-related adverse events in patients with advanced tumors treated with PD-1/PD-L1 inhibitors[J]. Chinese Clinical Oncology, 2022, 27(2): 109-116. DOI: 10.3969/j.issn.1009-0460.2022.02.003.
|